Status:
RECRUITING
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Dry Eye
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Eligibility Criteria
Inclusion
- Be at least 18 years of age of either gender and any race.
- Provide written informed consent and sign the HIPAA form.
- Be willing and able to follow all instructions and attend all study visits.
Exclusion
- Use of any of the disallowed medications during the washout and study period.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT07179055
Start Date
October 1 2025
End Date
September 1 2026
Last Update
September 17 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
Newport Beach, California, United States, 92663
2
Vanda Investigational Site
Andover, Massachusetts, United States, 01810
3
Vanda Investigational Site
Shelby, North Carolina, United States, 28150
4
Vanda Investigational Site
Memphis, Tennessee, United States, 38119